ENDRA Life Sciences (NASDAQ:NDRA) Downgraded by Zacks Investment Research

Zacks Investment Research lowered shares of ENDRA Life Sciences (NASDAQ:NDRA) from a buy rating to a hold rating in a research report sent to investors on Tuesday, Zacks.com reports.

According to Zacks, “ENDRA Life Sciences Inc. is a developer of enhanced ultrasound technologies. ENDRA Life Sciences Inc. is based in Ann Arbor, United States. “

Separately, HC Wainwright restated a buy rating and set a $6.00 price target on shares of ENDRA Life Sciences in a research report on Monday, November 18th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. ENDRA Life Sciences has a consensus rating of Buy and an average target price of $4.00.

NDRA stock traded down $0.13 during trading on Tuesday, hitting $1.72. 195,332 shares of the company’s stock traded hands, compared to its average volume of 205,095. The company has a quick ratio of 1.54, a current ratio of 1.61 and a debt-to-equity ratio of 0.26. ENDRA Life Sciences has a 52 week low of $0.62 and a 52 week high of $3.49. The stock has a fifty day moving average price of $1.47 and a two-hundred day moving average price of $1.35. The stock has a market capitalization of $16.76 million, a price-to-earnings ratio of -1.21 and a beta of 1.52.

ENDRA Life Sciences (NASDAQ:NDRA) last released its quarterly earnings results on Wednesday, November 13th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.27). As a group, equities research analysts expect that ENDRA Life Sciences will post -0.98 EPS for the current fiscal year.

A hedge fund recently bought a new stake in ENDRA Life Sciences stock. Virtu Financial LLC bought a new stake in ENDRA Life Sciences Inc (NASDAQ:NDRA) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 28,541 shares of the company’s stock, valued at approximately $30,000. Virtu Financial LLC owned approximately 0.38% of ENDRA Life Sciences as of its most recent SEC filing. 12.24% of the stock is currently owned by institutional investors.

About ENDRA Life Sciences

ENDRA Life Sciences Inc develops medical imaging technology based on the thermos-acoustic effect that improves the sensitivity and specificity of clinical ultrasound. It offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding.

Read More: Recession

Get a free copy of the Zacks research report on ENDRA Life Sciences (NDRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ENDRA Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ENDRA Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.